FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration

Laboratory Investigation

Volumn 90, Issue 1, 2010, Pages 9-19

  Hwang, Su Jin ^a,b   Kim, Ji Hyung ^a   Kim, Hye Young ^a,c   Kim, Sanghee ^a   Chung, Doo Hyun ^a  

^a Seoul National University   (South Korea)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cytokine; FTY720; Inhibition; Migration; NKT cells; S1P1 receptor

Indexed keywords

CD1D ANTIGEN; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; SPHINGOSINE 1 PHOSPHATE RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIGENS, CD1D; ARTHRITIS, EXPERIMENTAL; CELL MOVEMENT; CYTOKINES; GATA3 TRANSCRIPTION FACTOR; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; PROPYLENE GLYCOLS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, GABA-A; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; T-LYMPHOCYTES;

EID: 73349109123     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.109     Document Type: Article

References (55)

1. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
2. + and CD4~8~ T cells in mice and humans. J Exp Med 1994;180:1097-1106.
3. Bendelac A. CD1: presenting unusual antigens to unusual T lymphocytes. Science 1995;269:185-186.
4. Kim HY, Kim HJ, Min HS, et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor fT1 production. J Exp Med 2005;201:41-47.
5. Kim HJ, Hwang SJ, Kim BK, et al. NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor beta, and by clonally deleting antigen-specific T cells. Immunology 2006;118:101-111.
6. Kim JH, Kim HY, Kim S, et al. Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. Am J Pathol 2005;167:1231-1241.
7. Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001;7: 1057-1062.
8. Seino KI, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 2001;98:2577-2581.
9. Kim JH,Choi EY, Chung DH. Donor bone marrow type II (non-Va14Ja18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-y and IL-4. J Immunol 2007;179:6579-6587.
10. Hwang SJ, Kim S, Park WS, et al. IL-4-secreting NKT cells prevent hypersensitivity pneumonitis by suppressing IFN-g-producing neutrophils. J Immunol 2006;177:5258-5268.
11. Cui J, Shin T, Kawano T, et al. Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-1626.
12. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002;195:617-624.
13. Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006;12(20 Pt 1):6079-6086.
14. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582-588.
15. Tupin E, Nicoletti A, Elhage R, et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004;199:417-422.
16. Yatomi Y, Yamamura S, Ruan F, et al. Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J Biol Chem 1997;272: 5291-5297.
17. Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21:1202-1209.
18. von Wenckstern H, Zimmermann K, Kleuser B. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. Arch Immunol Ther Exp (Warsz) 2006;54:239-251.
19. Schwab SR, Pereira JP, Matloubian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005;309:1735-1739.
20. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360.
21. Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J 2005;19:1731-1733.
22. Idzko M, Panther E, Corinti S, et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 2002;16:625-627.
23. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349.
24. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-553.
25. + T cells. J Immunol 2003;170:3662-3670.
26. Allende ML, Zhou D, Kalkofen DN, et al. S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB J 2008;22:307-315.
27. Kim S, Lee H, Lee M, et al. Efficient synthesis of the immunosuppressive antigen FTY720. Synthesis 2006;2006:752-755.
28. Albert R, Hinterding K, Brinkmann V, et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 2005;48:5373-5377.
29. Kim SLS, Lee T, Jung S, et al. Practical synthesis of KRN7000 form phytosphingosine. Synthesis 2004;22:847-850.
30. West Jr RE, Moss J, Vaughan M, et al. Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site. J Biol Chem 1985;260:14428-14430.
31. Windh RT, Lee MJ, Hla T, et al. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J Biol Chem 1999;274:27351-27358.
32. Van Brocklyn JR, Graler MH, Bernhardt G, et al. Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood 2000;95:2624-2629.
33. Malek RL, Toman RE, Edsall LC, et al. Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. J Biol Chem 2001;276:5692-5699.
34. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005;12:703-715.
35. Yopp AC, Ledgerwood LG, Ochando JC, et al. Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant 2006;20:788-795.
36. + T cells produce large amounts of IL-4 and IFN-g upon activation by anti-CD3 or CD1. J Immunol 1997;159:2240-2249.
37. Zhang DH, Cohn L, Ray P, et al. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 1997;272:21597-21603.
38. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-596.
39. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
40. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8:1337-1344.
41. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005;108:308-319.
42. Kurashima Y, Kunisawa J, Higuchi M, et al. Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy. J Immunol 2007;179:1577-1585.
43. Honig SM, Fu S, Mao X, et al. FTY720 stimulates multidrug transporter-and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 2003;111:627-637.
44. Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004;173:855-865.
45. Brinkmann V, Chen S, Feng L, et al. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001;33:530-531.
46. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160: 5037-5044. (Pubitemid 28215340)
47. Yanagawa Y, Hoshino Y, Kataoka H, et al. FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. Transplant Proc 1999;31:1227-1229.
48. Brinkmann V, Pinschewer D, Chiba K, et al. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000;21:49-52.
49. Yanagawa Y, Sugahara K, Kataoka H, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998;160: 5493-5499.
50. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008;111:275-284.
51. Nagahara Y, Enosawa S, Ikekita M, et al. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 2000;48:75-85.
52. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-168.
53. Idzko M, Hammad H, van Nimwegen M, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006;116:2935-2944.
54. Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-and collagen-induced arthritis in rats. Int J Immunopharmacol 2000;22:323-331.
55. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501-508.